China Headquarters

US Division

ABOUT US

Focused on the discovery and clinical development of innovative biologics for unmet medical needs

>
Leadership

Leadership

Mingjiu Chen, Ph.D.

Founder, Chairman and Chief Executive Officer

 

Dr. Chen is the CEO of Biosion, Inc. Before establishing Biosion, Dr. Chen served as Senior Director of Monoclonal Antibody Operations at SDIX, Inc., where he led the team responsible for innovative antibody discovery services for biotech and pharmaceutical companies. Dr. Chen joined SDIX from Abbott Laboratories (now AbbVie), where he made critical contributions to several innovative biologic programs including ABT165 (now in Phase-II). Dr. Chen has over 20 years of antibody development experience in the biotech and pharmaceutic industries with expertise in competitive innovative discovery and preclinical development. Dr. Chen received his Ph.D. degree in Molecular Medicine from the University of Texas Health Science Center at San Antonio.

 

 

 

Hugh M. Davis, Ph.D

Chief Operating Officer & President of Biosion USA, Inc.

 

Dr. Davis brings to Biosion over 30 years of experience in the biotech and pharmaceutical industries. Dr. Davis joined Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer, leading the company to a very successful IPO in May of 2019. Prior to Frontage, Dr. Davis worked with Johnson & Johnson where he served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001. During his tenure in J&J, Hugh and his team were instrumental in the development and approval of many biologic therapies including Remicade, Stelara, Simponi, Sylvant, Darzalex and Tremfya.  Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at Glaxo SmithKline from 1996 to 2001.  Dr. holds a Ph.D. degree in Biochemistry from Villanova University and completed Post-Doctoral training at Centocor, Inc. (now Janssen R&D, LLC)

 

 

 

Mark Ma, Ph.D.

Vice President, Head of Integrated Antibody Platform

 

Dr. Ma brings to Biosion over 30 years of experience in cancer biology and transgenic research, target validation and preclinical studies.  Before joining Biosion, Dr. Ma served as Director of Research and Development at FZata, Inc., where he led the team responsible for developing therapeutic nanobodies to various targets.  Previously, he was a faculty member at the University of Maryland and a Senior Scientist at Lexicon Pharmaceuticals, Inc.  Dr. Ma received his Ph.D. degree in Biotechnology from the University of Milan, Italy and completed postdoctoral training at Baylor College of Medicine.

 

 

 

 

Mike Liu, Ph. D., MBA

Dr. Liu has multiple years of experience in licensing & business development, market development, and biomedical research. He was on the Executive Committee of Sino-American Pharmaceutical Professionals Association (SAPA) from 2004 to 2010. From 2016 to June 2020, Dr. Liu was Senior Vice President of Global Corporate Development at Alphamab, a leading innovative biotech company in China. He was primarily responsible for global business development initiatives and closed multiple deals licensing, research collaboration and strategic partnership. From 2011 to May 2016, Dr. Liu was Head of Global Business Development at Hengrui Pharmaceuticals. At Hengrui, he closed dozens of licensing and partnership agreements with leading multi-national and Chinese companies, such as the $795-million out-licensing deal with Incyte for PD-1 mAb and in-licensing of Rolapitant from Tesaro. Prior to Hengrui, Dr. Liu held increasing responsibilities for global commercial development at Alexion Pharmaceuticals and licensing & business development at Purdue Pharma L.P., a leading private pharmaceutical company in the U.S. He closed multiple deals in commercialization partnering, product acquisition, licensing, and research alliance. Dr. Liu obtained his bachelor degree in biochemistry at Nanjing University, Ph.D. degree in cancer biology at Eppley Cancer Institute in the US, and MBA degree at Washington University in St. Louis. In his earlier academic career, Dr. Liu conducted translational medical research at Yale University School of Medicine.